Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014
NEW YORK, April 28, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014
http://www.reportlinker.com/p02088196/Metastatic-Ovarian-Cancer-Global-Clinical-Trials-Review-H1-2014.html
Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014
Summary
GlobalData's clinical trial report, "Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Ovarian Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Ovarian Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Ovarian Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Introduction 6
Metastatic Ovarian Cancer 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Clinical Trials by G7 Countries: Proportion of Metastatic Ovarian Cancer to Oncology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Metastatic Ovarian Cancer to Oncology Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Unaccomplished Trials of Metastatic Ovarian Cancer 24
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Metastatic Ovarian Cancer Therapeutics Clinical Trials 29
Prominent Drugs 31
Latest Clinical Trials News on Metastatic Ovarian Cancer 32
Jan 09, 2014: Synta Announces Launch of GANNET53, a Randomized, pan-European Study of Ganetespib in p53 Mutant, Metastatic Ovarian Cancer 32
Mar 18, 2013: Merrimack Pharma Completes Enrollment In Phase II Study Of MM-121 In Combination With Paclitaxel In Patients With Platinum-resistant Or Refractory Advanced Ovarian Cancers 32
Mar 06, 2013: Ziopharm Oncology Announces Initiation Of Indiana University-sponsored Phase II Study Of Palifosfamide In Recurrent And Incurable Germ Cell Tumors 33
Dec 28, 2011: Researchers Reveal Targeted Therapy Extends Progression-Free Survival Of Patients With Advanced Ovarian Cancer 33
Clinical Trial Profiles 35
Clinical Trial Overview of Top Companies 35
F. Hoffmann-La Roche Ltd. 35
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 35
MolMed S.p.A. 36
Clinical Trial Overview of MolMed S.p.A. 36
Isis Pharmaceuticals, Inc. 37
Clinical Trial Overview of Isis Pharmaceuticals, Inc. 37
E. Merck KG 38
Clinical Trial Overview of E. Merck KG 38
Daiichi Sankyo Company, Limited 39
Clinical Trial Overview of Daiichi Sankyo Company, Limited 39
AbbVie Inc. 40
Clinical Trial Overview of AbbVie Inc. 40
Eli Lilly and Company 41
Clinical Trial Overview of Eli Lilly and Company 41
Cell Therapeutics, Inc. 42
Clinical Trial Overview of Cell Therapeutics, Inc. 42
California Stem Cell, Inc. 43
Clinical Trial Overview of California Stem Cell, Inc. 43
Bristol-Myers Squibb Company 44
Clinical Trial Overview of Bristol-Myers Squibb Company 44
Clinical Trial Overview of Top Institutes / Government 45
National Cancer Institute 45
Clinical Trial Overview of National Cancer Institute 45
NCIC Clinical Trials Group 47
Clinical Trial Overview of NCIC Clinical Trials Group 47
University of Washington 48
Clinical Trial Overview of University of Washington 48
The University of Texas Health Science Center at San Antonio 49
Clinical Trial Overview of The University of Texas Health Science Center at San Antonio 49
Rutgers, The State University of New Jersey 50
Clinical Trial Overview of Rutgers, The State University of New Jersey 50
European Organization for Research and Treatment of Cancer 51
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 51
Albert Einstein College of Medicine of Yeshiva University 52
Clinical Trial Overview of Albert Einstein College of Medicine of Yeshiva University 52
Karolinska Institutet 53
Clinical Trial Overview of Karolinska Institutet 53
Weill Cornell Medical College 54
Clinical Trial Overview of Weill Cornell Medical College 54
Five Key Clinical Profiles 55
Appendix 79
Abbreviations 79
Definitions 79
Research Methodology 80
Secondary Research 80
About GlobalData 81
Contact Us 81
Disclaimer 81
Source 82
List of Tables
Metastatic Ovarian Cancer Therapeutics, Global, Clinical Trials by Region, 2014* 7
Metastatic Ovarian Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Metastatic Ovarian Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Metastatic Ovarian Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Metastatic Ovarian Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Metastatic Ovarian Cancer Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Metastatic Ovarian Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Proportion of Metastatic Ovarian Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 14
Metastatic Ovarian Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Metastatic Ovarian Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 16
Proportion of Metastatic Ovarian Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 17
Metastatic Ovarian Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 18
Metastatic Ovarian Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 19
Metastatic Ovarian Cancer Therapeutics, Global, Clinical Trials by Phase, 2014* 20
Metastatic Ovarian Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 21
Metastatic Ovarian Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Metastatic Ovarian Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Metastatic Ovarian Cancer Therapeutics, Global, Suspended Clinical Trials, 2014* 24
Metastatic Ovarian Cancer Therapeutics, Global, Withdrawn Clinical Trials, 2014* 24
Metastatic Ovarian Cancer Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Metastatic Ovarian Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Metastatic Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Metastatic Ovarian Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Metastatic Ovarian Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Metastatic Ovarian Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
Metastatic Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 35
Metastatic Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by MolMed S.p.A., 2014* 36
Metastatic Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Isis Pharmaceuticals, Inc., 2014* 37
Metastatic Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by E. Merck KG, 2014* 38
Metastatic Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Daiichi Sankyo Company, Limited, 2014* 39
Metastatic Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by AbbVie Inc., 2014* 40
Metastatic Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 41
Metastatic Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Cell Therapeutics, Inc., 2014* 42
Metastatic Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by California Stem Cell, Inc., 2014* 43
Metastatic Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 44
Metastatic Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 45
Metastatic Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by NCIC Clinical Trials Group, 2014* 47
Metastatic Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Washington, 2014* 48
Metastatic Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas Health Science Center at San Antonio, 2014* 49
Metastatic Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Rutgers, The State University of New Jersey, 2014* 50
Metastatic Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014* 51
Metastatic Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Albert Einstein College of Medicine of Yeshiva University, 2014* 52
Metastatic Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Karolinska Institutet, 2014* 53
Metastatic Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Weill Cornell Medical College, 2014* 54
List of Figures
Metastatic Ovarian Cancer Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Metastatic Ovarian Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Metastatic Ovarian Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Metastatic Ovarian Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Metastatic Ovarian Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Metastatic Ovarian Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Proportion of Metastatic Ovarian Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 14
Metastatic Ovarian Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Metastatic Ovarian Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 16
Proportion of Metastatic Ovarian Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 17
Metastatic Ovarian Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 18
Metastatic Ovarian Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 19
Metastatic Ovarian Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2014* 20
Metastatic Ovarian Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 21
Metastatic Ovarian Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Metastatic Ovarian Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Metastatic Ovarian Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Metastatic Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Metastatic Ovarian Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Metastatic Ovarian Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Metastatic Ovarian Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
GlobalData Methodology 80
To order this report: Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014
http://www.reportlinker.com/p02088196/Metastatic-Ovarian-Cancer-Global-Clinical-Trials-Review-H1-2014.html
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article